List of Excipients in Branded Drug GLYNASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	GLYNASE	glyburide	0009-0341	LACTOSE
Pharmacia & Upjohn Company LLC	GLYNASE	glyburide	0009-0341	MAGNESIUM STEARATE
Pharmacia & Upjohn Company LLC	GLYNASE	glyburide	0009-0341	SILICON DIOXIDE
Pharmacia & Upjohn Company LLC	GLYNASE	glyburide	0009-0341	STARCH, CORN

Glynase Excipient Strategy and Commercial Opportunities for Glyburide Tablets

Last updated: August 17, 2026

Glynase is the former brand for micronized glyburide, also known as glibenclamide, an oral sulfonylurea for type 2 diabetes. Its core commercial opportunity is generic or private-label supply of immediate-release tablets, not preservation of a high-value brand franchise. The formulation is relatively simple, but micronized glyburide creates meaningful control points around particle size, dissolution, content uniformity, and food-related exposure.

The Glynase PresTab formulation uses micronized glyburide with lactose, microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate. These excipients support a conventional compressed-tablet platform with rapid disintegration and manufacturing scalability.[1]

What is Glynase and how is it formulated?

Glynase PresTab contains micronized glyburide in 1.5 mg, 3 mg, and 6 mg strengths. The product is an immediate-release oral tablet. The active ingredient stimulates pancreatic insulin secretion and carries a recognized risk of prolonged hypoglycemia, particularly in older adults, patients with renal or hepatic impairment, and patients with irregular food intake.[1]

Glynase formulation profile

Attribute	Glynase PresTab profile
Active ingredient	Micronized glyburide
International nonproprietary name	Glibenclamide
Dosage form	Immediate-release tablet
Strengths	1.5 mg, 3 mg, 6 mg
Therapeutic class	Sulfonylurea
Route	Oral
Core indication	Type 2 diabetes mellitus
Key formulation issue	Low-dose uniformity and dissolution of micronized API
Main excipients	Lactose, microcrystalline cellulose, povidone, sodium starch glycolate, magnesium stearate
Regulatory pathway for copy products	ANDA, subject to applicable FDA requirements
Biosimilar relevance	None; glyburide is a small molecule

The formulation does not rely on an elaborate delivery system, enteric coating, extended-release matrix, or device component. The principal technical value is in reproducing the performance of micronized glyburide in a robust tablet process.

What excipients are used in Glynase tablets?

The FDA labeling identifies lactose, microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate as inactive ingredients in Glynase PresTab.[1]

Excipient	Primary function	Commercial and technical relevance
Lactose	Diluent and compressibility aid	Supports tablet mass and processing efficiency; creates a lactose-intolerance and labeling consideration for some markets
Microcrystalline cellulose	Filler, dry binder, and compression aid	Improves tablet strength and supports direct compression
Povidone	Binder	Improves granule cohesion and content uniformity, especially at low API loading
Sodium starch glycolate	Superdisintegrant	Promotes tablet breakup and supports immediate-release dissolution
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion; excessive use can slow wetting and dissolution

The commercial formulation does not require a novel excipient. Each named excipient is widely used in approved oral solid dosage forms and is listed in FDA’s Inactive Ingredient Database for pharmaceutical use.[2]

Why the excipient system matters for micronized glyburide

Glyburide has low aqueous solubility. Micronization increases surface area and can improve dissolution, but it also raises processing risks. Fine particles may agglomerate, segregate during blending, or adhere to manufacturing equipment. Those effects can produce variability in tablet potency and dissolution.

Povidone and microcrystalline cellulose help maintain blend and tablet integrity. Sodium starch glycolate offsets the risk that compression and hydrophobic lubrication will delay tablet disintegration. Magnesium stearate concentration and mixing time require tight control because over-lubrication can reduce wettability and slow dissolution.

For a generic developer, the excipient formula alone is not sufficient. The critical package includes:

• Glyburide particle-size distribution
• API surface-area and agglomeration profile
• Blend uniformity at 1.5 mg and 3 mg strengths
• Granulation or direct-compression process
• Lubrication time and shear exposure
• Tablet hardness and friability
• Disintegration and dissolution profiles
• Stability under humidity and accelerated conditions

What excipient strategy should a Glynase generic use?

The lowest-risk strategy is to begin with a close qualitative and quantitative composition, or Q1/Q2 approach, using the labeled excipients. A conventional immediate-release tablet minimizes regulatory and manufacturing complexity.

Recommended baseline strategy

A generic manufacturer should use a formulation platform with:

1. Micronized glyburide controlled to a narrow particle-size range.
2. Microcrystalline cellulose as the principal compression aid.
3. Povidone at a level sufficient to preserve blend uniformity without creating an overly dense granule.
4. Sodium starch glycolate positioned to produce rapid disintegration.
5. Magnesium stearate added late in the process and mixed for a controlled time.
6. Lactose retained initially unless supply, labeling, or market-access considerations favor a substitute.

The 1.5 mg strength is the most demanding. The low API load increases the risk of blend segregation and potency variability. A manufacturer may need geometric dilution, ordered mixing, granulation, or a validated premix to achieve acceptable content uniformity.

Alternative excipient platforms

Platform	Potential benefit	Main risk
Lactose plus microcrystalline cellulose	Closest to legacy formulation; strong manufacturability	Lactose supply and labeling considerations
Mannitol-based formulation	Improved mouthfeel and potential use in orally disintegrating products	Higher cost and different compaction behavior
Dibasic calcium phosphate	Strong compression and low hygroscopicity	Potentially slower disintegration and less favorable dissolution
Copovidone-based binder system	Better granule strength and process flexibility	May increase formulation complexity
Crospovidone-based disintegrant	Rapid wicking and tablet breakup	Different dissolution behavior from sodium starch glycolate
Lactose-free formulation	Expands certain dietary and contract-manufacturing opportunities	Requires new comparative dissolution and bioequivalence work

A switch from lactose to another diluent is commercially feasible, but the change should be treated as a development program rather than a simple substitution. The critical endpoints are dissolution similarity, content uniformity, tablet robustness, and bioequivalence.

What manufacturing and intellectual-property barriers affect Glynase?

The intellectual-property barrier around legacy micronized glyburide tablets is likely low relative to newer diabetes products. The principal barrier is execution: reproducing the clinical and pharmaceutical performance of a low-dose, poorly soluble drug in a scalable process.

Manufacturing barriers

The main barriers are:

• Reliable supply of micronized glyburide
• Control of electrostatic and cohesive fine-particle behavior
• Uniform distribution of low-dose API
• Consistent dissolution across commercial-scale batches
• Prevention of magnesium-stearate over-lubrication
• Stability protection against moisture and temperature stress
• Validation of multiple strengths on one manufacturing platform

A manufacturer that uses a coarser API or a different milling profile may obtain acceptable assay results but fail comparative dissolution or bioequivalence. For this product, API particle engineering is part of the finished-product strategy.

Patent and exclusivity position

Glynase is a legacy small-molecule product. Any original regulatory exclusivity and conventional product patent protection associated with its initial development would have expired years ago. No biosimilar pathway applies because glyburide is not a biologic.

The relevant regulatory review should focus on:

• Current Orange Book listings for glyburide products
• Whether any listed patents remain active for a specific reference product
• Whether a reference product is currently marketed
• Whether the proposed product is eligible for a standard ANDA
• Whether labeling differences require a suitability petition or another pathway

The commercial value of any remaining patent position would depend on its claim scope. A broad composition patent would be more significant than a narrow manufacturing or method-of-use patent, but legacy glyburide opportunities are generally more exposed to price competition than to patent blocking.

When does Glynase lose exclusivity and what is the generic entry risk?

Glynase’s meaningful exclusivity period has already elapsed. Generic entry risk is therefore high from a patent perspective, subject to product-specific Orange Book and marketing-status checks.

Generic launch scenarios

Scenario	Launch condition	Commercial implication
Standard ANDA launch	No blocking patent or exclusivity remains	Earliest and lowest-cost entry route
Paragraph IV launch	Applicant certifies that a listed patent is invalid, unenforceable, or not infringed	Litigation risk can delay approval or launch
Paragraph III launch	Applicant accepts an existing patent expiration date	Lower litigation risk; delayed entry
Authorized-generic supply	Brand owner or licensee supplies a generic equivalent	Can compress margins and deter independent entry
Private-label launch	Approved manufacturer supplies distributors or pharmacy chains	Lower commercial overhead but higher price pressure
Reformulated product	New dosage form or excipient platform	Requires added development and regulatory work

For Glynase, a Paragraph IV strategy would only be commercially rational if a currently listed patent creates a meaningful market delay and expected sales justify litigation exposure. A standard ANDA or contract-manufacturing approach is more consistent with the product’s legacy status.

What FDA regulatory issues affect Glynase generic development?

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. The product is a conventional immediate-release tablet, but glyburide’s low dose and dissolution behavior make the analytical package important.

Key FDA development requirements

The development program should address:

• Same active ingredient and dosage form
• Equivalent strength and route of administration
• Comparative dissolution across relevant pH conditions
• Content uniformity and assay
• Impurity and degradation-product control
• Stability under ICH conditions
• Bioequivalence under the applicable FDA product-specific guidance
• Labeling consistency with the reference product

The FDA Product-Specific Guidance database should be reviewed for the current glyburide recommendation before finalizing the study design.[3]

An applicant should not assume that matching the inactive-ingredient list guarantees approval. The FDA may focus on systemic exposure, early dissolution, and sensitivity to food or formulation differences. Micronized glyburide can create a narrow performance window in which small changes in particle size, granulation, or lubrication affect exposure.

What formulation patents could protect a new Glynase product?

A new formulation could pursue intellectual-property protection around a technical feature rather than the basic glyburide molecule. Potential claim areas include:

• Defined micronized glyburide particle-size distributions
• Stabilized glyburide dispersions
• Amorphous or co-processed glyburide systems
• Rapid-disintegration or orally disintegrating tablets
• Taste-masked dosage forms
• Fixed-dose combinations
• Controlled-release systems
• Manufacturing processes that reduce segregation
• Specific dissolution profiles linked to clinical performance

Patentability would depend on novelty, non-obviousness, enablement, and demonstrated technical benefit. A patent that merely substitutes one common diluent for another would face a weak inventive-step position unless it produces an unexpected result.

A stronger formulation program would link the excipient system to measurable performance, such as improved content uniformity at the 1.5 mg strength, reduced food effect, improved dissolution in biorelevant media, or enhanced stability.

What commercial opportunities exist for Glynase excipients and formulations?

The strongest opportunities are cost-led and access-led rather than premium-brand opportunities.

1. Low-cost generic supply

Glyburide tablets can be manufactured using common excipients and standard oral-solid-dose equipment. A supplier with validated micronization, efficient compression, and strong quality systems could compete for pharmacy, hospital, and institutional contracts.

2. Private-label and contract manufacturing

Distributors and regional pharmaceutical companies may seek low-volume or multi-strength supply without investing in their own development program. A three-strength platform can support private-label products if the manufacturer controls blend uniformity and packaging operations.

3. Lactose-free or excipient-differentiated products

A lactose-free version could provide a modest differentiation point. It would not create a strong clinical premium by itself, but it may help a manufacturer meet customer-specific formulation requirements.

4. Combination products

Glyburide could be evaluated in fixed-dose combinations with metformin or other oral antidiabetic agents. The commercial rationale is limited by the declining preference for sulfonylureas and the availability of newer therapies. A combination product would require clinical, regulatory, and formulation work beyond a standard ANDA.

5. Orally disintegrating and geriatric formulations

An orally disintegrating tablet could target patients with swallowing difficulty. The opportunity is constrained by glyburide-associated hypoglycemia risk and the need to demonstrate that rapid disintegration does not create undesirable exposure changes.

6. Emerging-market supply

Glyburide remains familiar in many international markets under the glibenclamide name. Opportunities may exist in markets where low-cost oral diabetes therapy remains important. Geographic strategy should account for local requirements, reference-product availability, excipient restrictions, and whether the product is recommended for older or higher-risk patients.

How does Glynase compare with newer diabetes products?

Glynase has a lower development and manufacturing cost than newer branded diabetes products, but its commercial ceiling is also lower.

Factor	Glynase/glyburide	Metformin	DPP-4 inhibitors	GLP-1 receptor agonists
Product type	Small-molecule tablet	Small-molecule tablet	Small-molecule tablet	Usually injectable or advanced oral product
Development complexity	Low to moderate	Low	Moderate	High
Patent barrier	Legacy or limited	Generally mature	Product-specific	Often substantial
Formulation opportunity	Micronization, dissolution, ODT, combinations	Release control, combinations	Release and combination products	Delivery systems and device technology
Price pressure	High	High	Moderate to high	Variable
Hypoglycemia risk	Meaningful	Low when used alone	Low when used alone	Low when used alone
Premium potential	Limited	Limited to moderate	Moderate	Higher for differentiated products

Glynase is therefore better suited to a volume, tender, and access strategy than to a premium innovation strategy.

What is the revenue exposure and competitive outlook?

Revenue exposure depends on whether the product is sold as a branded product, a generic, or a contract-manufactured private label. The category is structurally price-sensitive because multiple sulfonylurea products and alternative diabetes therapies compete for the same patient population.

The main commercial risks are:

• Declining use of glyburide in favor of agents with lower hypoglycemia risk
• Substitution by metformin and newer therapies
• Generic price erosion
• Limited payer willingness to reimburse formulation premiums
• Clinical concerns affecting prescribing in elderly and renally impaired patients
• Reference-product discontinuation or limited availability
• Low barriers to entry for established oral-solid-dose manufacturers

The main commercial advantages are:

• Simple tablet platform
• Established API and excipient supply chains
• Multiple strengths
• No biologic manufacturing requirement
• No device dependency
• Potential for regional and institutional supply contracts

A manufacturer should model the opportunity using volume, tender price, API cost, packaging, bioequivalence expense, and expected generic erosion. A premium based only on excipient selection is unlikely to be sustainable without a clinically relevant performance claim.

What is the Key Takeaways for Glynase excipient strategy?

• Glynase is a micronized glyburide immediate-release tablet in 1.5 mg, 3 mg, and 6 mg strengths.
• The labeled excipients are lactose, microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate.
• The highest technical risks are low-dose content uniformity, micronized API handling, and dissolution control.
• A close conventional formulation is the lowest-risk generic strategy.
• Lactose-free, orally disintegrating, and fixed-dose combination products provide formulation-development options but limited premium potential.
• Patent and regulatory exclusivity are legacy issues; commercial competition is primarily price-based.
• No biosimilar pathway applies.
• The best near-term opportunities are generic, private-label, contract-manufactured, and regional supply.
• A differentiated formulation requires evidence of improved dissolution, stability, usability, or clinical performance.

FAQs about Glynase excipient and commercial opportunities

Is Glynase the same as glyburide?

Yes. Glynase PresTab is a brand formulation of micronized glyburide, also known as glibenclamide.

Does Glynase contain lactose?

The FDA label identifies lactose as an inactive ingredient in Glynase PresTab.[1] A lactose-free generic would require its own formulation and comparative-performance program.

Which excipient is most important for Glynase tablet disintegration?

Sodium starch glycolate is the primary disintegrant identified in the labeled formulation. Its performance depends on concentration, compression force, particle size, and the extent of magnesium-stearate lubrication.

Can a company patent a new glyburide excipient formulation?

Potentially. Patent protection may be available for a novel and non-obvious particle-engineering method, dispersion, dosage form, combination, dissolution profile, or manufacturing process. A routine excipient substitution would generally provide a weaker patent position.

Is a Glynase generic likely to face biosimilar competition?

No. Glyburide is a small-molecule drug. Competing products would follow generic-drug pathways, primarily through ANDAs, rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Glynase PresTab (micronized glyburide) prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development. FDA Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA Center for Drug Evaluation and Research.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary: Glyburide monograph. U.S. Pharmacopeial Convention.